Fig. 4From: Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim®) in the treatment of uncomplicated malaria at public health facilities in four African countriesDistribution of recurrent symptomatic parasitaemia cases among the seven sitesBack to article page